Transurethral enucleation resection of the prostate is safe and feasible for the treatment of symptomatic benign prostatic hyperplasia (BPH). However, long-term results of this treatment in patients with BPH have not been reported. To assess the efficacy and safety of this procedure, this study retrospectively evaluated long-term outcomes in 1400 consecutive patients who underwent transurethral enucleation resection of the prostate for BPH between 2008 and 2014. Patients were followed up at 1, 3, 6, and 12 months, and every year thereafter. At a median follow-up of 70.1 months, mean Qmax increased from 6.43 to 22.1 ml/s and mean IPSS decreased from 22.3 to 2.9. PVR decreased from 123.0 to 12.0 cc, and mean TRUS volume decreased from 65.4 to 21.4 ml (P<0.0000). QOL score improved from 4.96 to 1.0, and PSA concentrations decreased from 6.87 to 0.75 ng/ml (P<0.0000). Complications included bladder neck contracture in 1.0% of patients and urethral stricture in 1.3%. These long-term results showed that transurethral enucleation resection of the prostate is durable, safe, and effective for patients with BPH, with patients not requiring reoperation.
| Published in | Journal of Surgery (Volume 4, Issue 2) |
| DOI | 10.11648/j.js.20160402.18 |
| Page(s) | 40-44 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2016. Published by Science Publishing Group |
Benign Prostatic Hyperplasia, Transurethral Resection of the Prostate, Follow-up
| [1] | Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, et al. EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction. Eur Urol 2013; 64: 118-40. |
| [2] | Hawary A, Mukhtar K, Sinclair A, Pearce I. Transurethral resection of the prostate syndrome: almost gone but not forgotten. J Endourol 2009; 23: 2013-20. |
| [3] | Gilling PJ, Wilson LC, King CJ, Westenberg AM, Frampton CM, Fraundorfer MR. Long-term results of a randomized trial comparing holmium laser enucleation of the prostate and transurethral resection of the prostate: results at 7 years. BJU Int 2012; 109: 408-11. |
| [4] | Geavlete P. Is Classical Transurethral Resection of the Prostate, the Gold Standard Endoscopic Treatment for Benign Prostate Hyperplasia, in Real Danger of Being Replaced? Eur Urol 2010; 58: 349-55. |
| [5] | Xu A, Zou Y, Li B, Liu C, Zheng S, Li H, et al. A Randomized Trial Comparing Diode Laser Enucleation of the Prostate with Plasmakinetic Enucleation and Resection of the Prostate for the Treatment of Benign Prostatic Hyperplasia. J Endourol 2013; 27: 1254-1260. |
| [6] | Liu C, Zheng S, Li H, Xu k. Transurethral enucleation and resection of prostate in patients with benign prostatic hyperplasia by plasma kinetics. J Urol 2010; 184: 2440-5. |
| [7] | Rao JM, Yang JR, Ren YX, He J, Ding P, Yang JH. Plasmakinetic enucleation of the prostate versus transvesical open prostatectomy for benign prostatic hyperplasia >80 mL: 12-month follow-up results of a randomized clinical trial. Urology 2013; 82: 176-81. |
| [8] | Ou R, Deng X, Yang W, Wei X, Chen H, Xie K. Transurethral enucleation and resection of the prostate vs transvesical prostatectomy for prostate volumes >80 mL: a prospective randomized study. BJU Int 2013; 112: 239-245. |
| [9] | Zhao Z, Zeng G, Zhong W, Mai Z, Zeng S, Tao X. A prospective, randomised trial comparing plasmakinetic enucleation to standard transurethral resection of the prostate for symptomatic benign prostatic hyperplasia: three-year follow-up results. Eur Urol 2010; 58: 752-8. |
| [10] | Fayad AS, Sheikh MG, Zakaria T, Elfottoh HA, Alsergany R. Holmium laser enucleation versus bipolar resection of the prostate: a prospective randomized study. Which to choose? J Endourol 2011; 25: 1347-52. |
| [11] | Elmansy HM, Kotb A, Elhilali MM. Holmium laser enucleation of the prostate: long-term durability of clinical outcomes and complication rates during 10 years of followup. J Urol 2011; 186(5): 1972-6. |
| [12] | Krambeck AE, Handa SE, Lingeman JE. Experience with more than 1,000 holmium laser prostate enucleations for benign prostatic hyperplasia. J Urol 2010; 183: 1105-9. |
| [13] | Elmansy H, Baazeem A, Kotb A, Badawy H, Riad E, Emran A, et al. Holmium laser enucleation versus photoselective vaporization for prostatic adenoma greater than 60 ml: preliminary results of a prospective, randomized clinical trial. J Urol 2012; 188: 216-21. |
| [14] | Elshal AM, Elmansy HM, Elhilali MM. Feasibility of holmium laser enucleation of the prostate (HoLEP) for recurrent/residual benign prostatic hyperplasia (BPH). BJU Int 2012; 110: E845-50. |
| [15] | Reich O, Gratzke C, Stief CG. Techniques and long-termresults of surgical procedures for BPH. Eur Urol 2006; 49: 970–8. |
| [16] | Neill MG, Gilling PJ, Kennett KM, Frampton CM, Westenberg AM, Fraundorfer MR, et al. Randomized trial comparing Holmium laser enucleation of prostate with plasmakinetic enucleation of prostate for treatment of benign prostatic hyperplasia. Urology 2006; 68: 1020-4. |
| [17] | Kuntz RM, Lehrich K, Ahyai S. Transurethral holmium laser enucleation of the prostate compared with transvesical open prostatectomy: 18-month follow-up of a randomized trial. J Endourol 2004; 18: 189-91. |
| [18] | Kuntz RM: Current role of lasers in the treatment of benign prostatic hyperplasia (BPH). Eur Urol 2006; 49: 961-9. |
| [19] | Seki N, Mochida O, Kinukawa N, Sagiyama K, Naito S. Holmium laser enucleation for prostatic adenoma: analysis of learning curve over the course of 70 consecutive cases. J Urol 2003; 170: 1847-50. |
| [20] | Elshal AM, Elmansy HM, Elkoushy MA, Elhilali MM. Male sexual function outcome after three laser prostate surgical techniques: a single center perspective. Urology 2012; 80: 1098-104. |
APA Style
Bin Pan, Zhihai Deng, Genlong Jiao, Caiyong Lai, Zexuan Su, et al. (2016). Long-term Follow-up of Transurethral Enucleation Resection of the Prostate for Symptomatic Benign Prostatic Hyperplasia. Journal of Surgery, 4(2), 40-44. https://doi.org/10.11648/j.js.20160402.18
ACS Style
Bin Pan; Zhihai Deng; Genlong Jiao; Caiyong Lai; Zexuan Su, et al. Long-term Follow-up of Transurethral Enucleation Resection of the Prostate for Symptomatic Benign Prostatic Hyperplasia. J. Surg. 2016, 4(2), 40-44. doi: 10.11648/j.js.20160402.18
AMA Style
Bin Pan, Zhihai Deng, Genlong Jiao, Caiyong Lai, Zexuan Su, et al. Long-term Follow-up of Transurethral Enucleation Resection of the Prostate for Symptomatic Benign Prostatic Hyperplasia. J Surg. 2016;4(2):40-44. doi: 10.11648/j.js.20160402.18
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.js.20160402.18,
author = {Bin Pan and Zhihai Deng and Genlong Jiao and Caiyong Lai and Zexuan Su and Junfeng Liu},
title = {Long-term Follow-up of Transurethral Enucleation Resection of the Prostate for Symptomatic Benign Prostatic Hyperplasia},
journal = {Journal of Surgery},
volume = {4},
number = {2},
pages = {40-44},
doi = {10.11648/j.js.20160402.18},
url = {https://doi.org/10.11648/j.js.20160402.18},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.js.20160402.18},
abstract = {Transurethral enucleation resection of the prostate is safe and feasible for the treatment of symptomatic benign prostatic hyperplasia (BPH). However, long-term results of this treatment in patients with BPH have not been reported. To assess the efficacy and safety of this procedure, this study retrospectively evaluated long-term outcomes in 1400 consecutive patients who underwent transurethral enucleation resection of the prostate for BPH between 2008 and 2014. Patients were followed up at 1, 3, 6, and 12 months, and every year thereafter. At a median follow-up of 70.1 months, mean Qmax increased from 6.43 to 22.1 ml/s and mean IPSS decreased from 22.3 to 2.9. PVR decreased from 123.0 to 12.0 cc, and mean TRUS volume decreased from 65.4 to 21.4 ml (P<0.0000). QOL score improved from 4.96 to 1.0, and PSA concentrations decreased from 6.87 to 0.75 ng/ml (P<0.0000). Complications included bladder neck contracture in 1.0% of patients and urethral stricture in 1.3%. These long-term results showed that transurethral enucleation resection of the prostate is durable, safe, and effective for patients with BPH, with patients not requiring reoperation.},
year = {2016}
}
TY - JOUR T1 - Long-term Follow-up of Transurethral Enucleation Resection of the Prostate for Symptomatic Benign Prostatic Hyperplasia AU - Bin Pan AU - Zhihai Deng AU - Genlong Jiao AU - Caiyong Lai AU - Zexuan Su AU - Junfeng Liu Y1 - 2016/05/06 PY - 2016 N1 - https://doi.org/10.11648/j.js.20160402.18 DO - 10.11648/j.js.20160402.18 T2 - Journal of Surgery JF - Journal of Surgery JO - Journal of Surgery SP - 40 EP - 44 PB - Science Publishing Group SN - 2330-0930 UR - https://doi.org/10.11648/j.js.20160402.18 AB - Transurethral enucleation resection of the prostate is safe and feasible for the treatment of symptomatic benign prostatic hyperplasia (BPH). However, long-term results of this treatment in patients with BPH have not been reported. To assess the efficacy and safety of this procedure, this study retrospectively evaluated long-term outcomes in 1400 consecutive patients who underwent transurethral enucleation resection of the prostate for BPH between 2008 and 2014. Patients were followed up at 1, 3, 6, and 12 months, and every year thereafter. At a median follow-up of 70.1 months, mean Qmax increased from 6.43 to 22.1 ml/s and mean IPSS decreased from 22.3 to 2.9. PVR decreased from 123.0 to 12.0 cc, and mean TRUS volume decreased from 65.4 to 21.4 ml (P<0.0000). QOL score improved from 4.96 to 1.0, and PSA concentrations decreased from 6.87 to 0.75 ng/ml (P<0.0000). Complications included bladder neck contracture in 1.0% of patients and urethral stricture in 1.3%. These long-term results showed that transurethral enucleation resection of the prostate is durable, safe, and effective for patients with BPH, with patients not requiring reoperation. VL - 4 IS - 2 ER -
Email: